{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=afatinib&page=2",
    "query": {
      "intervention": "afatinib",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=afatinib&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T14:45:29.469Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03157089",
      "title": "Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-11-02",
      "completion_date": "2020-01-13",
      "has_results": true,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03157089"
    },
    {
      "nct_id": "NCT02271906",
      "title": "The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-07-01",
      "completion_date": "2017-08-16",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02271906"
    },
    {
      "nct_id": "NCT02762877",
      "title": "Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Genomic Health®, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2016-04",
      "completion_date": "2019-06-19",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 9,
      "location_summary": "Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Belleville",
          "state": "New Jersey"
        },
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762877"
    },
    {
      "nct_id": "NCT04439136",
      "title": "Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Afatinib Dimaleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-08-12",
      "completion_date": "2027-03-03",
      "has_results": true,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439136"
    },
    {
      "nct_id": "NCT01647711",
      "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Dose escalation followed by treatment with MTD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647711"
    },
    {
      "nct_id": "NCT01522768",
      "title": "Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib and Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2012-03",
      "completion_date": "2023-02-20",
      "has_results": true,
      "last_update_posted_date": "2023-11-01",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522768"
    },
    {
      "nct_id": "NCT02423525",
      "title": "Safety Study of Afatinib for Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Afatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santosh Kesari",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-12",
      "completion_date": "2021-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423525"
    },
    {
      "nct_id": "NCT01814553",
      "title": "ADAM-Afatinib Diarrhea Assessment and Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "afatinib",
          "type": "DRUG"
        },
        {
          "name": "loperamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01814553"
    },
    {
      "nct_id": "NCT00727506",
      "title": "BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        },
        {
          "name": "TMZ",
          "type": "DRUG"
        },
        {
          "name": "BIBW 2992 plus TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2008-07-14",
      "completion_date": "2016-05-25",
      "has_results": true,
      "last_update_posted_date": "2017-08-15",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00727506"
    },
    {
      "nct_id": "NCT00656136",
      "title": "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 585,
      "start_date": "2008-04",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-07-26",
      "last_synced_at": "2026-09-22T14:45:29.469Z",
      "location_count": 14,
      "location_summary": "Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more",
      "locations": [
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656136"
    }
  ]
}